REPL News and Press, Replimune Group Inc. From 12/07/22

Replimune Group ( NASDAQ: REPL ), a biotech focused on cancer immunotherapies, announced a collaboration with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) on Wednesday to study combination therapies for colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Per the terms of the ...

RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of 36% and complete response (CR) rate of 20%, with clinically meaningful activity across a broad range of anti-PD1 failed cutaneous mela...

RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma (HCC) Includes cost sharing for development in third-line CRC and second-line HCC ...

WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a firesi...

WOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team will host an investor even...

Replimune Group press release ( NASDAQ: REPL ): Q2 GAAP EPS of -$0.79 misses by $0.01 . As of September 30, 2022, cash, cash equivalents and short-term investments were $371.8 million, as compared to $395.7 million as of fiscal year end March 31, 20...

Replimune Group ( NASDAQ: REPL ) has secured a $200M non-dilutive term loan facility from Hercules Capital. The loan facility consists of up to six tranches, five of which can be drawn at the company's option and each maturing in October 2027. An initial $30M tranche w...

WOBURN, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it has obtained a $200 million non-dilutive term loan f...

U.S. stock markets have been exceedingly volatile in 2022. This turbulent environment hasn't kept some of the world's best investors on the sidelines, however. The billionaire brothers Julian and Felix Baker -- co-owners of the biotechnology focused hedge fund Baker Bros. Advisors -- ar...

Shares have lost half of their value since my March 2021 update. Currently, in ROTY we own 8% portfolio weighting with 20% gain. Key pivotal readouts are coming up year end (anti PD-1 failed melanoma) and Q1 2023 (CERPASS CSCC). Recent developments strengthen bullish thesis, inclu...